Venex (Diosmin)

Quick links to important sections

Venex (Diosmin)

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Venex (Diosmin)

Property Description
Active ingredient Diosmin
Form Tablet or Capsule (Oral solid forms)
Pharmacological class Phlebotonic, Venotropic agent
General purpose Supports healthy venous circulation
Origin Semi-synthetic bioflavonoid glycoside

Venex (Diosmin): Defining the Bioflavonoid and Pharmaceutical Class

Venex is a pharmaceutical preparation whose primary active ingredient is Diosmin (INN: Diosmin), a compound chemically classified as a bioflavonoid glycoside. This substance is a semisynthetic molecule, indicating it is derived from natural sources, such as certain citrus fruit extracts, and then extensively purified and modified to ensure optimal quality and efficacy. The final product is typically formulated for oral administration as a tablet or capsule.

Diosmin is formally categorized under the Anatomical Therapeutic Chemical (ATC) classification system with the code C05CA03, identifying it as a capillary stabilizing agent. As a phlebotonic, its core function is directed toward providing targeted support to the structure and resilience of the venous system, a property that is recognized by vascular specialists.

The General Purpose and High-Level Action of Phlebotonics

The general purpose of medications containing Diosmin is to provide targeted support for vascular health, specifically focusing on the function of veins and capillaries. Diosmin belongs to the pharmacological class known as phlebotonic and venotropic agents. Diosmin aids in improving the tone of the venous walls, which helps strengthen the vessels and supports proper blood flow.

The high-level action of Diosmin involves two primary effects: enhancing venous tone and reducing capillary permeability. By increasing the firmness of the vein walls and reducing fluid leakage from the capillaries, the compound helps to alleviate uncomfortable sensations often related to impaired blood return. This class of agents is used to relieve symptoms associated with venous disorders. The medication's general use scenario is to support comfort in patients experiencing the subjective feeling of heavy or tired legs.

What side effects are possible with Venex (Diosmin)?

Possible Side Effects and Safety Information

Official regulatory documents classify adverse reactions to Venex (Diosmin) based on the body systems affected and how frequently they are expected to occur. It is important to note that most recorded side effects are generally mild and may not require the medicine to be stopped.

Frequency-Classified Adverse Reactions

Adverse reactions are grouped by their rate of occurrence as documented in clinical studies and post-marketing surveillance:

Classification Body System Affected Examples of Reactions
Common (may affect up to 1 in 10 people) Gastrointestinal Disorders Diarrhea, dyspepsia (indigestion), nausea, vomiting
Nervous System Disorders Malaise (general feeling of discomfort)
Rare (may affect up to 1 in 1,000 people) Skin and Subcutaneous Tissue Disorders Rash, pruritus (itching), urticaria (hives)
Frequency Not Known Immune System Disorders Hypersensitivity reactions, including swelling of the face, lips, or eyelids; Quincke's edema (angioedema)

Serious Adverse Reactions and Safety Considerations

The most clinically significant adverse reaction reported, although its exact frequency is Not Known, is a hypersensitivity reaction. This includes the severe, localized swelling of the face, lips, tongue, or throat, known as Quincke's edema (angioedema), which requires immediate medical attention.

Official safety documents also indicate the potential for drug-drug interactions. Diosmin may affect the way certain other medicines are processed in the body, specifically those that are substrates for transport pumps like P-glycoprotein or specific CYP450 enzymes (e.g., CYP3A4). This interaction may alter the blood levels of those co-administered drugs.

Overdose and Emergency Response

Overdose and When to Seek Help

According to official regulatory prescribing information, overdose scenarios for Venex (Diosmin) are typically characterized by an intensification of known adverse effects. Experience with overdose is described as limited in official documentation.

Documented Overdose Manifestations

Reported symptoms often involve the gastrointestinal and neurological systems, and generally present as non-severe distress.

System Affected Documented Manifestations
Gastrointestinal Nausea, vomiting, diarrhea, abdominal discomfort
Nervous/Other Headache, pruritus (itching), rash

No specific severe or life-threatening outcomes are formally highlighted in regulatory documents as characteristic of a Diosmin overdose alone.

Official Emergency Actions and Management

In the event of a suspected overdose, official guidance requires the patient to seek medical attention immediately. Consultation with a doctor or pharmacist is mandated to evaluate the situation.

The management approach is strictly defined by regulatory authorities as symptomatic and supportive treatment. Since no specific antidote is known for this compound, treatment focuses on clinical monitoring and managing the symptoms that manifest. The decision for hospital observation is dictated entirely by the clinical presentation and severity of the symptoms. Regulatory labels do not specify population-based overdose considerations.

Therapeutic Uses of Venex (Diosmin)

What Venex (Diosmin) Treats: Main Uses and Benefits

The medication is commonly used to help with situations involving certain distressing symptoms related to impaired venous circulation. The medication is considered relevant for easing two main clinical presentations: venous circulation disorders and acute haemorrhoidal attacks. The verified therapeutic applications are used in supportive symptomatic management.

Diosmin is applied across conditions presenting with systemic or localized discomfort, primarily helping to address symptom clusters that may become intense or disruptive, such as the persistent feelings of heavy legs, aching, and leg swelling (oedema) associated with Chronic Venous Insufficiency (CVI). It is also used in areas where short-term symptom management is appropriate, particularly for the acute manifestations of haemorrhoidal disease, including localized pain and bleeding.

“It contributes to supportive relief, which may help patients cope more steadily with the chronic symptom burden.”

This medication is relevant when supportive symptom management is appropriate, such as during phases when symptoms become more noticeable or create temporary functional strain.


Quick Fact: Support for Heavy Legs
Venex is commonly used to help address symptom clusters that create noticeable functional strain, such as the feeling of heavy and tired legs, which are characteristic symptoms of compromised venous circulation.

Regulatory References

  1. FDA Philippines Patient Information Leaflet for Diosmin + Hesperidin

Eligibility and Restrictions for Use

The official regulatory profile for Venex (Diosmin) defines which populations are permitted, restricted, or prohibited from using the medicine.

The only absolute contraindication is for patients with a known hypersensitivity (allergy) to the active substance, Diosmin, or to any of the product’s excipients.

Use is formally established only for Adults (18 years and older). However, official labeling restricts or limits use for several other key populations:

Population Group Regulatory Status Basis for Restriction
Children / Adolescents Not Recommended Safety and efficacy not established (under 18 years).
Pregnant Women Not Recommended Precautionary measure due to limited clinical data.
Breastfeeding Women Not Recommended Absence of data on excretion into human milk.
Renal/Hepatic Impairment Limited Use Efficacy and safety have not been studied in these populations.

These eligibility rules emphasize that all non-adult and special physiological groups are subject to formal restrictions based on the explicit limitations of the available regulatory data, or known allergy status.

What should I know about interactions with other medicines?

The official regulatory profile for Venex (Diosmin) is structured around documented constraints and formal statements regarding the lack of interaction data. This section details only the officially specified interaction patterns.

Formal Restrictions on Co-administration

Certain medicinal products are formally restricted or explicitly listed as combinations that should not be taken with Diosmin due to documented interaction concerns. This list includes specific oncology, immunosuppressant, and cardiac medications.

  • Prohibited Combinations: Doxorubicin, Vincristine, Sirolimus, Digoxin, and Colchicine.

Documented Interaction Status

Regulatory labels provide explicit statements on the current documented interaction status for Diosmin, particularly concerning metabolic pathways and food.

Interaction Category Regulatory Status
Metabolic/PK Studies No interaction studies have been performed; no clinically relevant drug interaction has been reported in post-marketing experience.
Caution Required Co-administration with Diclofenac and Fexofenadine requires informing a healthcare provider.
Food and Supplements Interaction with food and drink is documented as Not Applicable. Patients must inform their provider about Herbal Tonics/Supplements.
Timing Rules No mandatory dose separation or timing requirements are listed in official regulatory documents.

This official structure defines the constraints on concomitant use, focusing on specific prohibited substances and reporting the current state of clinical knowledge regarding general interaction pathways.

Mechanism of Action

Diosmin modulates venous tone and microvascular function. Its primary action involves prolonging the vasoconstrictor effect of norepinephrine on the venous wall, thereby decreasing venous capacitance. The flavone structure reduces capillary hyperpermeability by preserving the integrity of the endothelial glycocalyx. Furthermore, Diosmin exerts anti-inflammatory effects through the inhibition of NF-κB pathway activation, which leads to a decrease in the adhesion and migration of leukocytes to the endothelium. The compound also acts as a scavenger of reactive oxygen species (ROS), protecting endothelial cells from oxidative stress. This mechanism culminates in enhanced lymphatic function via increased frequency and amplitude of lymphatic contractions.

Dosage and Administration Information

Instruction Map: How to use Venex (Diosmin) — Administration Guidelines

This map summarizes the administration and dosing rules for the Diosmin-containing Micronized Purified Flavonoid Fraction (MPFF).


Administration Scope

Feature Instruction
Route of administration Oral route only, via tablets or film-coated tablets.
Dosing schedule Chronic Venous Insufficiency (CVI): 1000 mg MPFF daily. Acute Haemorrhoidal Attack: A short-term, tapering regimen: 3000 mg MPFF daily for 4 days, followed by 2000 mg MPFF daily for the next 3 days.
Timing in relation to meals (if applicable) Tablets must be taken at mealtimes (with food).
Age-group administration rules Use is limited to adults only. Safety and efficacy are not established in children and adolescents under 18 years of age.
Missed-dose rules If a dose is forgotten, it is advised not to take a double dose to compensate for the missed one.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral solid (tablet).
Frequency pattern Once daily for chronic management; Multiple divided doses for short-term acute regimens.
Basis of use Standardized administration protocols and patient information.
Use-context constraints The total course duration for acute episodes is restricted to 7 days.

Resulting Procedural Structure

Step sequence:

  • The tablet is taken by mouth, swallowed whole with a glass of water.
  • Administration is tied directly to the time of a meal.
  • The higher dose for acute symptoms is tapered down after four days to complete the short-term course.

Connection to the overall use protocol (2–4 sentences): The instructions establish a standardized protocol that dictates the oral route of administration and ties intake to mealtimes. The regimen is structured to clearly separate the dose and frequency required for short-term acute management from the long-term daily maintenance dose, and restricts use to the adult population. For certain tablets, the score line must not be used for dose division, only to facilitate swallowing.

Recent Clinical Evidence

Research evidence / Overview of studies for Venex (Diosmin)


Evidence for Use in Chronic Venous Insufficiency Symptoms

Research examined Diosmin primarily through Randomized Controlled Trials (RCTs), and these trials have been collected and analyzed in numerous Systematic Reviews and Meta-analyses. These studies explored symptom patterns in adults diagnosed with different degrees of Chronic Venous Insufficiency (CVI).

The outcomes that researchers examined included patient-reported outcomes describing perceived discomfort, such as scoring the intensity of pain, feelings of heavy legs, and presence of nocturnal cramps. Studies also monitored objective outcomes related to systemic or functional imbalance, such as measurements of leg circumference to assess oedema. Findings describe patterns observed in the studies where some trials reported measurements of changes in these subjective symptom scores over defined observation periods. Research highlights changes measured during the study period, and some trials reported patterns in the measurements of objective signs such as swelling (oedema).

What remains uncertain is the long-term view of the patterns measured. Follow-up durations were limited, commonly spanning from 4 to 6 months. There is limited information for long-term outcomes that would describe the durability of observed patterns over several years. Furthermore, the evidence quality varies across studies due to methodological differences (high heterogeneity).


Evidence for Use in Acute Haemorrhoidal Attacks

Diosmin was evaluated in research contexts involving fluctuating or unstable symptoms, specifically for supportive management during acute haemorrhoidal attacks. Studies explored outcomes related to episodic or acute changes, such as the severity of pain and the presence of bleeding during the flare-up.

These studies were often conducted during periods of increased symptom activity. Findings describe patterns observed in the studies related to short-term symptom changes. Trials reported how symptoms evolved in the observed populations, and findings describe patterns observed in the studies related to pain and bleeding during the acute phase. Studies focusing on episodes where symptoms become more noticeable typically had short-term follow-up durations, covering the span of the acute event (e.g., 1 to 3 months).

Data for certain groups remain insufficient for single-agent Diosmin. The research scenarios explored short-term symptom changes, and there is limited information for long-term outcomes related to repeated or chronic haemorrhoidal episodes.

Frequently Asked Questions (FAQ)

Common questions about Venex (Diosmin) (FAQ)


Q: How long does it usually take to notice anything after starting Venex?

Studies examining the symptoms of venous disorders have often reported initial changes within a specific period. Clinical information describes symptom changes being observed in some studies within approximately two to four weeks of initiation.


Q: Is Venex something that needs to be taken long-term?

Venex is officially indicated for the symptomatic treatment of Chronic Venous Insufficiency, which is by nature a chronic condition. The maximum course duration for acute conditions, such as hemorrhoidal attacks, is officially restricted to seven days, but for chronic management, regulatory documents do not define a specific maximum duration of continuous use.


Q: What happens if a dose of Venex is missed?

Official guidelines advise that if a dose is missed, individuals should continue with the next scheduled dose as usual. Official labeling advises against taking a double dose to compensate for the missed one.


Q: Can Venex be taken with coffee or tea?

Official regulatory documents categorize the interaction status of Venex with food and drink as 'Not Applicable.' This means that no specific restriction or prohibition is placed on general beverages like coffee or tea when taking this medicine.


Q: Is Venex absorbed differently if taken with food?

The official instruction map requires that the tablets must be taken at mealtimes (with food). This mandatory timing is typically established to support the body's processing of the medicine, as required by official documentation.


Q: Can Venex cause weight changes or fluid retention?

Adverse reactions listed in official documents are grouped by how often they may occur. Weight changes and fluid retention (as a side effect caused by the medicine) are not included in the official lists of common or rare adverse reactions.


Q: Are there any specific foods or drinks that should be avoided when taking Venex?

Official regulatory information on drug interactions indicates that the status regarding food and drink is 'Not Applicable.' This means that no specific foods or drinks are officially listed as needing to be avoided while taking this medicine.


Q: Is it normal to feel a mild stomach upset when first starting Venex?

Official safety documents classify gastrointestinal disorders as a common side effect, meaning they may affect up to 1 in 10 people. These common reactions can include diarrhea, indigestion, nausea, and vomiting.


Q: What is the purpose of Diosmin in treating conditions like venous insufficiency?

Diosmin is classified as a phlebotonic agent. Its purpose in treating conditions like venous insufficiency is described as providing targeted support to the venous system by enhancing venous tone and reducing the leakage of fluid from the small blood vessels. This action supports the structural integrity and resilience of the vessel walls, based on its function as a phlebotonic agent.


Q: Is Venex considered an anti-inflammatory medication?

The drug's primary classification is as a phlebotonic and capillary stabilizing agent. However, the mechanism of action is described in regulatory documents as involving an anti-inflammatory effect through the inhibition of certain internal signaling pathways.


Q: Are there any known interactions between Venex and common vitamins like Vitamin C or D?

Official safety information states that no specific interaction has been formally reported for common vitamins. However, regulatory labels advise informing a healthcare provider about all herbal tonics or supplements being used.


Q: Is it true that Venex helps with poor circulation?

Venex's mechanism of action is focused on supporting vascular health. It is described as enhancing venous tone and improving the function of small blood vessels (microvascular function), which supports healthy venous circulation.


Q: Can Venex be used by older adults (e.g., over 65)?

Official documentation establishes use for adults (18 years and older). No specific cautions or contraindications are mandated solely for the older adult population in the regulatory labeling.


Q: Is Venex covered by research for managing varicose veins?

Yes, research has examined Diosmin for symptomatic relief associated with Chronic Venous Insufficiency (CVI). CVI is the underlying condition that leads to manifestations such as varicose veins.


Q: What is the shelf life of Venex tablets?

The official shelf life approved in regulatory documents is typically four years from the date of manufacture. This is dependent on maintaining the mandated storage conditions, which include keeping it in the original packaging at a maximum temperature of 30 C.


Q: What is the ingredient Diosmin made from?

Diosmin is chemically classified as a semi-synthetic bioflavonoid glycoside. This means the ingredient is originally derived from natural plant sources, such as certain citrus fruit extracts, and then is extensively purified and modified for pharmaceutical use.


Q: Is there a maximum time Venex can be used continuously?

The maximum course duration for acute conditions, such as hemorrhoidal attacks, is officially restricted to seven days. For the chronic management of venous insufficiency symptoms, regulatory documents do not define a specific maximum duration of continuous use.


Q: Does Venex change how other medications are absorbed?

Official safety documents indicate that Diosmin may affect how certain other medicines are processed in the body by interacting with specific transport pumps and enzymes. This interaction can potentially alter the blood levels of co-administered drugs.


Q: Can Venex make me feel dizzy or drowsy?

Official side effect classifications list malaise (a general feeling of discomfort) as a common reaction. Drowsiness and dizziness are not listed among the most common or rare adverse reactions in the official frequency classification.


Q: Is the evidence for Venex mainly based on small studies?

The research evidence includes analyses that collect data from multiple Randomized Controlled Trials (RCTs) and systematic reviews, suggesting findings are not based solely on small-scale studies.


Q: How is Diosmin described as working on blood vessels?

Diosmin is described as acting on the vascular system by increasing venous tone (firmness) and normalizing capillary permeability (reducing fluid leakage). This is intended to help support the structure and resilience of the blood vessel walls.


Q: Is Venex useful for treating general leg swelling (edema)?

Yes, studies have specifically monitored and examined objective outcomes related to systemic imbalance, such as measurements of leg circumference to assess oedema (swelling) associated with Chronic Venous Insufficiency.


Q: What are the typical expected benefits described in clinical studies?

Clinical studies have focused on patient-reported outcomes describing discomfort. Researchers have examined and reported patterns related to the intensity of symptoms like pain, feelings of heavy legs, and the presence of nocturnal cramps associated with venous disorders.


Q: Can taking Venex affect my sleep?

The research evidence for Venex includes studies that examine symptoms of Chronic Venous Insufficiency that may interfere with sleep. This specifically includes looking at the presence and intensity of nocturnal cramps.


Q: Does Venex cause dry mouth?

Dry mouth is not listed as one of the officially classified adverse reactions (Common, Rare, or Frequency Not Known) in the official safety information.


Q: Is it common for people to stop taking Venex due to side effects?

Official safety documents indicate that most recorded side effects are generally mild. These documents classify the side effects and state they may often not require the medicine to be stopped.


Q: What is the known safety profile of Venex for long-term use?

The overall safety profile is primarily based on the frequency-classified adverse reactions reported in studies and post-marketing surveillance. While long-term outcome data is limited, the official safety documentation does not suggest new serious adverse reactions develop with extended use beyond the known risk of hypersensitivity.


Q: Can Venex be used alongside compression stockings?

Patient information leaflets often note that combining the medicine with a healthy lifestyle is a way to support benefits. This includes measures such as increasing physical activity and wearing special support stockings to help stimulate blood circulation.


Q: What are the key findings from research on Venex and venous leg ulcers?

Studies have evaluated the use of Diosmin for managing severe stages of Chronic Venous Insufficiency. This includes scenarios involving venous ulceration and the potential for delayed healing related to the underlying condition.

How should Venex (Diosmin) be stored and disposed of?

Storage and Disposal of Venex (Diosmin)

Official regulatory documents define specific conditions to maintain the stability and safety of Diosmin tablets.

Storage Requirements

Labeled Storage Temperature Requirements: Store at a maximum temperature of 30°C.
Packaging-Related Storage Rules: The product must be kept in the original carton or outer packaging for protection.
Child-Protection Storage Requirements: Keep out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

When the medication is no longer needed or has expired, it must be disposed of according to established protocols. Do not throw away any medicines via wastewater or household waste. Consult a pharmacist or a local waste disposal program for guidance on proper pharmaceutical waste handling to ensure environmental protection.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Venex (Diosmin) found in:

A-Z Index: